Background Approximately 50% of newly diagnosed cases of non-small-cell lung cancer
(NSCLC) are observed in patients> 65 years, while 30%–40% of cases occur in patients> 70 …

Background Treating elderly non–small-cell lung cancer (NSCLC) patients in the salvage
setting is challenging because of concerns of intolerance to therapy. Here we report …

Lung cancer is the leading cause of cancer deaths in the Western countries. Recent
advancements in the treatment of non-small cell lung cancer (NSCLC) have led to an …

Purpose Comprehensive geriatric assessment (CGA) is recommended to assess the
vulnerability of elderly patients, but its integration in cancer treatment decision making has …

With a median age of 70 years at diagnosis, lung cancer is a disease of older persons. As a
consequence oncologists are confronted with an increasing older lung cancer population for …

Background Elderly patients with advanced non-small cell lung cancer (NSCLC) are thought
to receive suboptimal treatment mainly due to concerns for poor compliance and/or …

Background: In real-world practice, most patients with lung cancer are diagnosed when they
are aged≥ 65 years. However, clinical trials tend to lack data for the elderly population …

Lung cancer is the most common cause of cancer-related mortality in men and women. Non‑
small cell lung cancer (NSCLC) represents close to 90% of all lung cancers. When …

EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib changed
dramatically the history of metastatic non-small cell lung cancer (NSCLC) harbouring EGFR …

The efficacy of epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) in
elderly patients with non‑small‑cell lung cancer (NSCLC) remains uncertain. This …